CASI Pharmaceuticals is a US-based company with a global presence that develops and markets pharmaceutical products. Its portfolio includes EVOMELA for conditioning treatment and palliative care, and a product pipeline that includes CAR-T investigative products for B-cell acute lymphoblastic leukemia. They also have distribution and licensing agreements with international pharmaceutical companies and are based in Maryland.